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Abstract
Purpose—To determine if differences in screening and vaccination patterns across the 
population may accentuate ethnic and geographic variation in future burden of disease.
Methods—Using Cancer in North America data provided by the North American Association of 
Central Cancer Registries, county cervical cancer incidence trends from 1995 to 2009 were 
modeled for the entire United States using ecologic covariates. Rates for health service areas were 
also modeled by ethnicity. State-level incidence was mapped together with Papanicolaou (Pap) 
screening, past 3 years (women ≥ 18 years old), and three-dose human papillomavirus (HPV) 
vaccine coverage (girls 13 to 17 years old) to identify potential priority areas for preventive 
services.
Results—US cervical cancer incidence decreased more during the periods 1995 to 1999 and 
2000 to 2004 than during the period 2005 to 2009. During these 15 years, the most affected areas 
became increasingly confined to Appalachia, the lower Mississippi Valley, the Deep South, Texas, 
and Florida. Hispanic and black women experienced a higher incidence of cervical cancer than 
both white and Asian and Pacific Islander women during each period. Women in 10 of 17 states/
districts with a high incidence (≥ 8.14/100,000) reported low Pap testing (< 78.5%), HPV vaccine 
coverage (< 33.9%), or both prevention technologies.
Conclusion—The decline in cervical cancer incidence has slowed in recent years. Access to 
HPV vaccination, targeted screening, and treatment in affected populations is needed to reduce 
cervical cancer disparities in the future.
INTRODUCTION
Cervical cancer incidence and mortality in the United States have declined steadily in the 
decades since the adoption of cytology-based Papanicolaou (Pap) testing.1 Recently, cervical 
cancer death rates seem to have plateaued, and a slight decrease has been reported in the use 
of Pap testing.2 Cervical cancer disparities (the uneven distribution of burden to areas of 
lower socioeconomic status and minority ethnic groups) are increasing.3–6 Cervical cancer 
incidence is elevated among older and black women7,8 and in impoverished areas such as 
Appalachia, the lower Mississippi Valley, and the United States–Mexico border area.9 
Reduced access to screening services is a driving factor in these areas. Nationally, 3-year 
Pap screening completion is > 80% for women 21 to 65 years of age, with lower levels of 
screening among immigrants, minorities, the poor, and older women.10 Approximately 47% 
of girls born in the United States in 2000 had received at least one dose of human 
papillomavirus (HPV) vaccine by age 13 years.11 Safety concerns and views on sexual 
activity influence parental decisions regarding the vaccination of adolescent girls.11 
Although the safety and efficacy of the HPV vaccination is well established, in 2013, 38% of 
girls 13 to 17 years of age in the United States had completed the three-dose HPV vaccine 
series,11 far less than optimal.12 Because the reduction in cervical cancer incidence as a 
result of HPV vaccination will take decades to be realized,12 surveillance is needed to 
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identify communities with a higher burden of cervical cancer and to direct cervical cancer 
screening and vaccination services where they are needed most.1
To define high-priority areas for preventive services, we estimated small-area cervical cancer 
incidence, including by ethnicity, and mapped state-level incidence with percentage 
screening and HPV vaccination coverage.
METHODS
Incidence Data
The North American Association of Central Cancer Registries (NAACCR) provided a 
Cancer in North America data set with county-level incidence and population denominators 
for this analysis. A total of 36 of 50 state registries, all of which met NAACCR silver or gold 
standards for tumor registration data quality, gave active consent to include their incident 
cases in the analytic data set. For the years 1995 to 2009, complete or partial county-level 
cervical cancer incidence data were reported by NAACCR registries in areas covering 74% 
of the United States population. This included complete data from 1995 to 2009 for 22 states 
encompassing 56% of the population (Arizona, California, Colorado, Connecticut, Hawaii, 
Idaho, Illinois, Iowa, Kentucky, Louisiana, Maine, Michigan, Nebraska, New Jersey, New 
Mexico, New York, Pennsylvania, Rhode Island, Texas, Utah, Washington, and Wyoming) 
and multiple years of data for 14 states encompassing 18% of the population (Alaska, 
Arkansas, Georgia, Massachusetts, Mississippi, Montana, Nevada, North Carolina, North 
Dakota, South Carolina, South Dakota, Tennessee, Virginia, and West Virginia). In these 14 
states, data were missing for a median of 2 reporting years, generally the earliest reporting 
years. Two lower Mississippi Valley states were missing data for 1995 to 2003. The 
remaining 14 states and the District of Columbia, which did not provide data, accounted for 
26% of the US population.
Spatiotemporal Model
We developed a model similar in composition to one used commonly to predict current-year 
cancer incidence in the United States13 to estimate county-level cervical cancer incidence in 
5-year intervals from 1995 to 2009.14 The multivariable logistic regression model included a 
set of covariates selected through a forward and backward process. A generalized linear 
model was used (PROC GLIMMIX, SAS 9.3, SAS Institute, Cary, NC) with three random 
terms to account for spatial autocorrelation (longitude and latitude of the county), temporal 
autocorrelation (year of diagnosis), and residual autocorrelation of covariates. Missing 
cervical cancer incidence at the county level was modeled on the basis of the reported 
incidence in counties with comparable attributes. The incidence for counties with observed 
data was also updated according to model predictions to slightly adjust reported rates. The 
time periods of interest for modeled all-ethnicity county-level incidence were 1995 to 1999, 
2000 to 2004, and 2005 to 2009. To present incidence among ethnic groups, data were 
aggregated at the health service area (HSA) level,15 reducing instability from small counts at 
the county level. HSAs are either a single county or a cluster of contiguous counties that are 
relatively self-contained with respect to hospital care. Data were suppressed when there were 
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16 or fewer modeled incident cases. The accuracy of predicted rates for areas with missing 
data depends on how well covariates in the model predict the actual incidence.
Model Inputs
Demographic inputs of cervical incident cases were non-Hispanic ethnicity (hereafter 
referred to as white, black, American Indian and Alaska Native, and Asian and Pacific 
Islander), Hispanic ethnicity (all ethnicities), and age. County of residence was geocoded on 
the basis of latitude and longitude. County-level population estimates were obtained from 
the US Census Bureau Summary File for each year from 1995 through 2009. Incidence data, 
stratified by age (< 44, 45 to 64, and ⩾ 65 years) and year of diagnosis were retrieved using 
SEER*Stat 8.1.2 (Information Management Services, Calverton, MD).
County-level covariates included in the model were county-level rural-urban density data,16 
an Area Health Resources covariate enumerating the number of hospital-based physicians at 
the county level,15 and data on the percentages of the county population who were black, 
Asian and Pacific Islander, and American Indian and Alaskan Native. Cervical cancer 
mortality data reported by the National Center for Health Statistics were also included for 
each county in the United States. Socioeconomic covariates incorporated into the model 
were the percentage of the county population with income below the poverty level and the 
percentage of the population ⩾ 25 years of age with ⩾ 4 years of college education. The 
model also contained a variable indicating whether the county was in a National Program of 
Cancer Registries–funded area. The model provided estimates of county-level cervical 
cancer incidence for the entire United States, including areas and years with missing data as 
well as those with reported data. To illustrate geographic distributions in rates, modeled 
county estimates were mapped using 2000 Census county designations (ArcGIS 10.1; ESRI, 
Redlands, CA). In the all ethnicities combined model uncertainty related to small numbers 
was addressed with spatial smoothing. The population-weighted, nonparametric algorithm 
used universal Kriging after detrending.17 Data were approximately normally distributed and 
no transformations were applied, although first-order surface trend was removed. Smoothing 
was not applied to incidence maps of specific ethnic groups because of the potential for 
instability.
State-Level Incidence Trends
State-level modeled incidence trends on the basis of estimated age-standardized incidence 
were analyzed using joinpoint regression analysis (Joinpoint 3.5.0; Information Management 
Services). The technique fit a series of joined straight lines on a logarithmic scale for annual 
age-standardized rates.18 Using data from the model for each year, state trends were 
estimated for 5-year fixed intervals, or annual average percent change (AAPC), using 
weighted annual percent changes from joinpoint models.
Identification of Priority Areas
Three state-level variables were visualized: modeled cervical cancer incidence during the 
period 2005 to 2009, state-level proportions of women 21 to 65 years of age who had had a 
Pap test during the past 3 years19 estimated from pooled 2008 to 2010 responses to the 
National Health Interview Survey and Behavioral Risk Factor Surveillance System, and 
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HPV vaccination coverage by state (obtained from the National Immunization Survey of 
Teens performed during 2013)20 defined as the percentage of girls 13 to 17 years old who 
had received three doses or more of either the bivalent or the quadrivalent vaccine.
State-level cervical cancer incidence was mapped in tertiles (low, midlevel, and high 
incidence). Low incidence was 5.17 to 6.75, midlevel incidence ranged from 6.76 to 8.13, 
and high incidence was 8.14 to 9.76 cases per 100,000 women. Low state-level Pap 
screening coverage was defined as < 78.5%, midlevel as 78.5% to 81.4%, and high as 81.5% 
to 88.5%. Low state-level HPV vaccination uptake was defined as < 33.9%, midlevel as 
33.9% to 40.1%, and high as 40.2% to 56.5%. States in the bottom third distribution for 
three-dose HPV vaccine receipt (< 33.9%), Pap screening (< 78.5%), or both vaccine and 
Pap screening were depicted with horizontal, vertical, and crosshatched lines, respectively. 
The status of state Medicaid expansion as of January 2016 was also assessed.21
RESULTS
Modeled cervical cancer incidence and observed death rates per 100,000 women from 1995 
to 2009 are presented in Table 1. Incidence and death rates were highest among non-
Hispanic black followed by Hispanic women in each time period. Incidence and death rates 
decreased from the period 1995 to 1999 to the period 2005 to 2009 among all ethnic groups. 
Age-specific incidence per 100,000 women was highest among 45- to 64-year-old women, 
averaging 17.3 and decreasing from 20.5 during the period 1995 to 1999 to 15.2 during the 
period 2005 to 2009. The highest death rate was also seen among women > 65 years of age, 
averaging 7.0 and decreasing from 8.2 during the period 1995 to 1999 to 6.1 during the 
period 2005 to 2009.
Figure 1 displays the smoothed, county-level modeled estimates of cervical cancer incidence 
by time period. From 1995 to 1999, the highest incidence was found in counties extending 
south and west from Appalachia to southeastern Colorado, northeastern New Mexico, and 
Texas, with a low incidence found in southwestern New England, the Northern Plains, and 
Mountain West. During the period 2000 to 2004, elevated rates became more localized to 
central Appalachia, the Ohio River Valley, the Lower Mississippi River Valley, rural Texas 
including the Mexican border area, and the rural Southeast. During the period 2005 to 2009, 
areas with the highest incidence were even more contained within Appalachia, the lower 
Mississippi Valley, the Deep South, Texas, and Florida.
Overall, in the United States during 1995 to 1999, 2000 to 2004, and 2005 to 2009, the 
AAPC in modeled cervical cancer incidence declined significantly by −3.5, −3.1, and −1.1 
percent per year over successive periods (Data Supplement). This pattern of slowing but still 
statistically significant decreasing incidence trends in recent years was seen in 27 states. In 
nine states and in the District of Columbia, trends did not change significantly over the three 
time periods. In three states (Georgia, Virginia, and Louisiana) there was a nonsignificant 
increase in cervical cancer incidence between 2005 and 2009. In nine other states (Alaska, 
Tennessee, Maryland, New Jersey, South Carolina, South Dakota, Illinois, Iowa, and 
Oregon), the decrease in cervical cancer incidence during the period 2005 to 2009 was not 
statistically significant. In Utah and Oklahoma the AAPC during the period 1995 to 1999 
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was not statistically significant; however, incidence decreased significantly during more 
recent time periods.
Figure 2 presents modeled HSA-level incidence by ethnicity during the period 2005 to 2009. 
Color ranges vary by map. Higher cervical cancer incidence was seen among Hispanic and 
black than among white and Asian and Pacific Islander women. Among whites, incidence 
was highest in Appalachia, the Mississippi and Ohio River valleys, Indiana, and rural parts 
of Illinois, Texas, Louisiana, Arkansas, Oklahoma, Tennessee, Alabama, and Georgia. 
Isolated areas with high incidence were found in central California, northwestern Arizona, 
central Pennsylvania, southern New Jersey, and northern and central Florida. High modeled 
incidence areas for blacks were found in eastern Texas and adjacent areas of Oklahoma, 
Louisiana, and Arkansas. The incidence was also elevated along the Mississippi River Valley 
from Illinois to Tennessee, Arkansas, and Mississippi. Affected rural areas included adjacent 
areas of Mississippi and Alabama, and Georgia and north central Florida. A high incidence 
was also seen in northern and central Indiana, rural South Carolina, southern New Jersey, 
New York City, and southeastern Florida.
Of areas with large Hispanic populations, the regions with the highest modeled incidence 
included west Texas, central and southern Florida, and metropolitan Houston, Chicago, and 
New York. Among Asian and Pacific Islanders, a high modeled incidence was seen in 
central California and Houston, Texas; central and south Florida; and metropolitan New 
York. The incidence for American Indians/Alaska Natives was not presented because of low 
counts.
Figure 3 presents state-level modeled cervical cancer incidence during the period 2005 to 
2009. States are classified into three categories: low, midlevel, and high cervical cancer 
incidence states. States in the bottom tertile of Pap screening use and HPV vaccine uptake 
were classified as having low adoption of these preventive services. Sixteen states plus the 
District of Columbia, shown in red, had a high cervical cancer incidence. In two high-
incidence states, both Pap screening and HPV vaccine uptake were low (Arkansas and 
Nevada). There was a low proportion of Pap screening in three high-incidence states 
(Tennessee, West Virginia, and Indiana) and of HPV vaccine uptake in five high-incidence 
jurisdictions (District of Columbia, Mississippi, Illinois, Kentucky, and New Jersey). Many 
of the 16 states with a midlevel cervical cancer incidence (shown in orange) were adjacent to 
high-incidence states. One midlevel-incidence state (Missouri) had low uptake of both Pap 
screening and HPV vaccination. Among the midlevel-incidence states, five (New Mexico, 
Wyoming, Nebraska, Oklahoma, and Ohio) had a low percentage of Pap screening, and five 
(Alaska, Kansas, Maryland, North Carolina, and Georgia) had low vaccine uptake. States 
with the lowest cervical cancer incidence (shown in gold) were located in New England, the 
northern tier of states, the four corners region, and Virginia. In three low-incidence states 
(Montana, Idaho, and Utah), a low percentage of women received Pap screening, and a low 
percentage of girls received three doses of HPV vaccine. There was also a low percentage of 
Pap screening in Arizona, North Dakota, and South Dakota, and the percentage of girls in 
Virginia who received HPV vaccination was less than 33.9%.
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As of January 2016, six of 17 jurisdictions with the highest cervical cancer incidence had 
not expanded Medicaid coverage (Alabama, Florida, Mississippi, South Carolina, 
Tennessee, and Texas). Seven of 16 states with a midlevel cervical cancer incidence had not 
expanded Medicaid (Georgia, Kansas, Missouri, North Carolina, Nebraska, Oklahoma, and 
Wyoming). Among the 18 states with the lowest cervical cancer incidence, three had not 
expanded Medicaid (Idaho, Montana, and Utah).
DISCUSSION
This study suggests that the long-term decrease in US cervical cancer incidence is slowing 
down. This finding is consistent with the nonsignificant decreasing trend reported during the 
period 2005 to 2009 in areas in the United States with high-quality incidence data.12 High-
incidence geographic areas were confined increasingly to rural areas within Appalachia, 
Texas, the lower Mississippi Valley, and the southeastern United States. Hispanic and black 
women had a higher cervical cancer incidence than did white and Asian and Pacific Islander 
women. In 10 of 17 states/districts with a high cervical cancer incidence, there was low use 
of Pap screening or HPV vaccination. Locally tailored cervical cancer vaccination, 
screening, and treatment efforts that target poor women living in medically underserved 
geographic areas are needed to maintain progress in reducing cervical cancer disparities.
As recently as the 1970s, cervical cancer was a leading cause of cancer among US women; 
however, the incidence has decreased in subsequent decades.8 Trends in this study differ 
from sustained decreasing cervical cancer incidence trends over the past half-century, but are 
consistent with recent findings describing a leveling off of cervical cancer mortality2 and 
incidence12 in the United States. A possible explanation for the slowing of the decreasing 
trend is that women with access to health care are benefiting from preventive services such 
as Pap screening and HPV testing,2 to a greater extent than are women in medically 
underserved groups. These under-served women, who experience a higher burden of cervical 
cancer,23 include ethnic minorities, women from low socioeconomic backgrounds,5 and 
women living in impoverished geographic areas.10 Future progress to reduce the burden of 
cervical cancer depends on access to vaccination, screening, and treatment of these hard-to-
reach groups.24 Of note, some states with the highest incidence of cervical cancer have low 
percentages of Pap screening and HPV vaccine uptake. Provisions of the Affordable Care 
Act, which require most health insurance plans to cover cervical cancer screening and HPV 
vaccination with no cost sharing, could improve cervical cancer prevention among low-
income women.25
In this study spanning the years 1995 through 2009, there were progressively smaller areas 
with an elevated cervical cancer incidence over time. Regions with the highest burden of 
disease during the period 2005 to 2009 were largely contained to economically deprived 
counties within Appalachia, Texas, the lower Mississippi Valley, and the southeastern United 
States. The limited progress in reducing the incidence of this cancer in areas with slow 
economic development or an influx of immigrant populations is consistent with findings 
reported in Mexico,26 Brazil,27 and England.28
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Lack of awareness, lack of access to health care, and cultural beliefs are barriers to cervical 
cancer prevention within population subgroups.29–31 For instance, in Connecticut,32 
heterogeneity in the occurrence of cervical cancer precursors is reported. Culturally 
competent locally targeted outreach needs to be part of cervical cancer control programs. 
One study of African-American women living in the high cervical cancer mortality area of 
Sunflower County, Mississippi, indicated that door-to-door visits to offer home self-
collection HPV test kits increased participation in cervical cancer screening almost four-fold 
compared with clinic-based Pap testing alone.33 In a national study, predictors of not being 
screened for cervical cancer included not having made a physician office visit within the past 
12 months because of cost, minority ethnicity, lack of a high school diploma among 
residents of metropolitan areas, and self-reported fair or poor general health among non-
metropolitan area residents.34 The heterogeneity of underserved women suggests a need for 
screening and HPV vaccination outreach across broad areas.35
Other researchers have reported ethnic and geographic disparities in cervical cancer 
screening34 and incidence.36 In the United States–Mexico border area, Hispanic women 
were less likely than other women to have had a recent Pap test,37 and white women in 
Appalachia had higher rates of HPV infection compared with the US population.38 Although 
provider recommendation improves acceptance of HPV vaccination, minority and low-
income women are least likely to receive such recommendations.39 Cervical cancer 
prevention can be advanced through community-based interventions,40 particularly in 
communities with limited access to a formal health care system. These community-based 
interventions may be more effective than one-size-fits-all approaches.41–43
This study identified populations that would benefit from cervical cancer outreach by 
ethnicity, geography, and access to screening and HPV vaccination. Ongoing spatial analysis 
is recommended to monitor cervical cancer trends in the HPV vaccine era.44 Study 
limitations include missing data for some states, which was partially addressed with 
geospatial modeling. Furthermore, HPV vaccination data were available only at the state 
level. County-level data would improve prioritization of outreach to areas with a high 
cervical cancer burden. Despite limitations, the analysis identifies priority areas for 
interventions to improve screening and vaccination rates. Although progress has been made 
in reducing the incidence of cervical cancer, outreach is needed in low-socioeconomic areas 
of the United States. Provisions of the Affordable Care Act that eliminate cost sharing for 
cervical cancer screening and HPV vaccination in most health plans should reduce cost as a 
barrier to receiving these prevention services.
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Smoothed, county-level modeled US cervical cancer incidence per 100,000 women, 5-year 
intervals, 1995 to 2009.
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Modeled health services area–level cervical cancer incidence by ethnicity, 2005 to 2009.
Kish et al. Page 13














States with high, midlevel, and low cervical cancer incidence during the period 2005 to 
2009, further depicting states with low percentages of Papanicolaou (PAP) screening or 
human papillomavirus (HPV) vaccination. Less than 78.5% of women > 18 years old 
reported PAP screening in the past 3 years during the period 2008 to 2010, and, <33.9% of 
girls 13 to 17 years of age had received three doses of HPV vaccine as of 2013.
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